In summary, among individuals with HIV-associated NAFLD, GH axis augmentation with tesamorelin led to changes in hepatic gene expression that reflect an overall return toward liver health. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.